Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities: 2009-2025

Historic Total Liabilities for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $7.5 million.

  • China Pharma Holdings' Total Liabilities rose 7.98% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 7.98%. This contributed to the annual value of $7.1 million for FY2024, which is 20.80% down from last year.
  • As of Q3 2025, China Pharma Holdings' Total Liabilities stood at $7.5 million, which was up 2.55% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Total Liabilities ranged from a high of $16.6 million in Q4 2021 and a low of $6.9 million during Q2 2024.
  • Its 3-year average for Total Liabilities is $8.5 million, with a median of $7.5 million in 2025.
  • In the last 5 years, China Pharma Holdings' Total Liabilities grew by 26.83% in 2021 and then slumped by 39.63% in 2024.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Total Liabilities stood at $16.6 million in 2021, then declined by 18.87% to $13.5 million in 2022, then slumped by 33.20% to $9.0 million in 2023, then fell by 20.80% to $7.1 million in 2024, then climbed by 7.98% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $7.3 million for Q2 2025, and $7.2 million during Q1 2025.